Biomarkers and neuroimaging markers in Parkinson's disease.
10.1097/CM9.0000000000003745
- Author:
Dongning SU
1
;
Yuanchu ZHENG
2
;
Tao FENG
1
Author Information
1. Center for Movement Disorders, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
2. China National Clinical Research Center for Neurological Diseases, Beijing 100070, China.
- Publication Type:Journal Article
- Keywords:
Biomarker;
MRI;
Neuroimaging;
PET;
Parkinson’s disease;
α-synuclein
- From:
Chinese Medical Journal
2025;138(19):2365-2380
- CountryChina
- Language:English
-
Abstract:
Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide, highlighting the urgent need for improved diagnostic and therapeutic strategies. Biomarkers from cerebrospinal fluid (CSF), blood, and peripheral tissue hold promise for early PD detection. In addition, neuroimaging techniques, including magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), and positron emission tomography (PET), allow for detailed visualization of neurodegeneration and associated structural and functional brain changes. This review summarizes recent advances in PD biomarkers and neuroimaging, highlighting their diagnostic potential and implications for future research.
